ArticleFrontiers in oncology2022

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review.

Yan Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.